logo-loader
viewPreveCeutical Medical Inc.

PreveCeutical hires Australian patent experts Griffith Hack to secure intellectual property

It is looking to protect its IP developed in its four current research and development programs

legal texts gavel
The firm will be working with Griffith Hack’s Dr Kathryn Morris, a principal and patent attorney

PreveCeutical Medical Inc (CSE:PREV) (OTCMKTS:PRVCF), the health sciences company developing preventative therapies, is moving one step forward to secure its intellectual property, with the retention of a patent law firm. 

The Vancouver-based company has hired Australian legal experts Griffith Hack as its patent attorneys to protect its intellectual property and help obtain the necessary patents associated with its therapeutic research and development. 

“Following the successful completion of our novel designed peptides derived from Caribbean blue scorpion venom and with our two other programs coming to a close during 2020, we will need to ensure all our intellectual property is patented in order to protect its value,” PreveCeutical said in a statement.

READ: PreveCeutical Medical says it is moving towards proof of concept with its blue scorpion venom research

The firm will be working with Griffith Hack’s Dr Kathryn Morris, a principal and patent attorney, who has qualifications in organic chemistry and intellectual property law. 

Specifically, the team is looking to protect its intellectual property developed in its four current research and development programs with UniQuest and the University of Queensland, Australia.

"These patent filings are critical to PreveCeutical as we are now currently working to discuss potential of partnering with biotech and pharmaceutical companies to further the application of technologies for "out licensing" towards achieving targeted drug delivery for their active new chemical entities,” Dr Mak Jawadekar, PreveCeutical’s chief science officer said in a statement.

PreveCeutical is studying its Sol-gel nose-to-brain drug delivery system and non-addictive pain medication at the University of Queensland in the country.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: PreveCeutical Medical Inc.

Price: 0.035 CAD

CSE:PREV
Market: CSE
Market Cap: $13.88 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc. named herein, including the promotion by the Company of PreveCeutical Medical Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Preveceutical announces successful preliminary evaluation of...

Preveceutical (CSE:PREV-OTCQB: PRVCF) President Mak Jawadeker joined Steve Darling from Proactive Vancouver on Skype to discuss the company successfully completing the design, synthesis and preliminary evaluation of key peptides from its scorpion venom-derived peptide research and development...

on 15/11/19

2 min read